FDA Approves Otsuka Pharma's Alzheimer's Agitation Drug
TL;DR Summary
The FDA has approved Rexulti (brexpiprazole) oral tablets as the first treatment option for agitation associated with dementia due to Alzheimer's disease. Dementia is a serious and debilitating neurological condition characterized by progressive decline in one or more cognitive domains in the brain. Alzheimer's disease is the most common cause of dementia. The effectiveness of Rexulti for the treatment of agitation associated with dementia due to Alzheimer's disease was determined through two 12-week, randomized, double-blind, placebo-controlled, fixed-dose studies.
- FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer's Disease FDA.gov
- Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug Reuters
- Japan's Otsuka Pharma gets FDA approval for Alzheimer's agitation drug ETHealthWorld
- Japan’s Otsuka Pharma gets US FDA approval for Alzheimer’s agitation drug INQUIRER.net
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
89%
691 → 78 words
Want the full story? Read the original article
Read on FDA.gov